（文章来源：证券日报） 证券日报网3月23日讯 ，中煤能源在接受调研者提问时表示，公司前2个月产量波动主要受地质条件变 化，生产组织难度增加等因素影响。公司2026年度生产计划安排请以2025年度报告披露的数据为准。 ...

Group 1 - The core viewpoint of the article indicates that the company, China Coal Energy, is experiencing normal production in its coal chemical enterprises and anticipates an improvement in profitability due to rising product prices [1] Group 2 - The company suggests that detailed information regarding its financial performance will be disclosed in the upcoming quarterly report [1]

（文章来源：证券日报） 证券日报网3月23日讯 ，中煤能源在接受调研者提问时表示，公司榆林二期煤化工项目将于2026年底投 产，公司会根据各装置运行情况有序推动项目达产。 ...

Core Viewpoint - Rongchang Biopharmaceutical (09995) has received approval from the National Medical Products Administration of China for the drug registration certificate of Vedisituzumab (RC48), which is now approved for a new indication in treating HER2 low-expressing breast cancer with liver metastasis [1][2] Group 1: Drug Approval Details - The new indication is for adult breast cancer patients with unresectable or metastatic HER2 low-expressing (IHC 1+ or IHC 2+/ISH-) who have previously received at least one systemic treatment during the metastatic disease stage or have relapsed within 12 months after completing adjuvant chemotherapy [1] - This approval is based on data from a randomized, open-label, parallel-controlled, multi-center Phase III clinical trial (RC48-C012) conducted in China, which demonstrated good efficacy and safety for Vedisituzumab in this specific patient population [1] Group 2: Product Background - Vedisituzumab is the first original ADC independently developed in China, targeting the HER2 protein on tumor cells, and has achieved world-leading clinical data in trials for gastric cancer, urothelial carcinoma, and breast cancer [2] - With this latest approval, Vedisituzumab is now approved for four indications in China: HER2 overexpressing locally advanced or metastatic gastric cancer; HER2 overexpressing locally advanced or metastatic urothelial carcinoma; HER2 positive with liver metastasis in advanced breast cancer; and HER2 low-expressing with liver metastasis in breast cancer [2]

Core Viewpoint - Rongchang Biopharmaceutical (09995) has received approval from the National Medical Products Administration of China for the drug registration certificate of Vidixtimab (RC48), which is now approved for a new indication in treating HER2 low-expressing breast cancer with liver metastasis [1][2] Group 1 - The new indication is for adult breast cancer patients with unresectable or metastatic HER2 low-expressing (IHC 1+ or IHC 2+/ISH-) tumors who have previously received at least one systemic treatment during the metastatic disease stage or have relapsed within 12 months after adjuvant chemotherapy [1] - This approval is based on data from a randomized, open-label, parallel-controlled, multi-center Phase III clinical trial (RC48-C012) conducted in China, which demonstrated good efficacy and safety for Vidixtimab in this specific patient population [1] Group 2 - Vidixtimab is the first original ADC independently developed in China, targeting the HER2 protein on tumor cells, and has achieved world-leading clinical data in trials for gastric cancer, urothelial carcinoma, and breast cancer [2] - With this latest approval, Vidixtimab is now approved for four indications in China: HER2 overexpressing locally advanced or metastatic gastric cancer; HER2 overexpressing locally advanced or metastatic urothelial carcinoma; HER2 positive with liver metastasis in advanced breast cancer; and HER2 low-expressing with liver metastasis in breast cancer [2]

Core Viewpoint - Rongchang Biopharmaceutical (09995.HK) has received approval from the National Medical Products Administration of China for the drug registration certificate of Vidisichan (RC48), marking the fourth indication approved for this drug in the domestic market [1] Group 1 - The new indication is for the treatment of adult breast cancer patients with low HER2 expression (IHC1+ or IHC2+/ISH-) and liver metastasis, who have previously received at least one systemic treatment during the metastatic disease stage or have relapsed within 12 months after adjuvant chemotherapy [1] - The approval is based on data from a randomized, open-label, parallel-controlled, multi-center Phase III clinical trial (RC48-C012) conducted in China, which demonstrated good efficacy and safety of Vidisichan for this specific patient population [1]

Core Viewpoint - Xinhua Pharmaceutical announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., received the drug registration certificate for ibuprofen granules from the National Medical Products Administration, indicating a significant regulatory approval for a product aimed at pain relief and fever reduction [1] Company Summary - The approved ibuprofen granules are intended for alleviating mild to moderate pain, including headaches, joint pain, migraines, toothaches, muscle pain, neuralgia, and dysmenorrhea [1] - The product can also be used to reduce fever caused by common colds or influenza [1]

Core Viewpoint - Rongchang Biopharmaceutical has received approval from the National Medical Products Administration for the new indication of its drug, RC48 (brand name: Aidiqi®), for the treatment of HER2 low-expressing breast cancer with liver metastasis, marking the fourth approved indication for this drug in China [1] Company Summary - RC48 is the first original antibody-drug conjugate (ADC) developed independently by Rongchang Biopharmaceutical [1] - The drug has been approved for four indications: treatment of HER2 overexpressing locally advanced or metastatic gastric cancer, HER2 overexpressing locally advanced or metastatic urothelial carcinoma, HER2 positive with liver metastasis advanced breast cancer, and HER2 low-expressing with liver metastasis breast cancer [1]

Core Viewpoint - The China Bank Inner Mongolia Branch is implementing a three-dimensional model of "regulatory linkage + holiday empowerment + precise drip irrigation" to enhance financial consumer rights protection through a series of educational and promotional activities for the 2026 "3.15" International Consumer Rights Day [1] Group 1: Regulatory Linkage and Public Awareness - The China Bank Inner Mongolia Branch quickly responded to regulatory calls by forming a professional lecture team to participate in the "3.15" centralized publicity day, collaborating with regulatory agencies and industry peers to create a "one-stop" financial consulting service platform [2] - The activities focused on educating the public about eight basic rights of financial consumers, preventing telecom and online fraud, protecting personal information, and rational investment and financial management through case studies, interactive Q&A, and material distribution [2] Group 2: Cultural Integration and Community Engagement - The bank innovatively combined financial education with traditional cultural practices and special holidays, creating a "finance + holiday + folk customs" promotional model that enhances community engagement [3] - Activities included immersive educational events that combined anti-fraud knowledge with traditional crafts, and performances by local senior choirs to spread financial knowledge in a festive atmosphere [3] Group 3: Targeted Education for Vulnerable Groups - The bank has tailored its educational outreach to different demographic groups, including the elderly, youth, and new employment groups, focusing on their specific financial risks and needs [5][7] - For the elderly, the bank provides specialized sessions on common scams and teaches them to use financial tools safely, while for youth, it addresses risks associated with student loans and online scams through engaging formats like skits and quizzes [7] - New employment groups, such as drivers and delivery personnel, receive information on financial policies and security measures to protect against scams related to low-interest loans and fraudulent job offers [7] Group 4: Future Initiatives - The China Bank Inner Mongolia Branch plans to continue enhancing financial consumer protection efforts by innovating promotional methods and integrating consumer rights education into daily operations [8]

Group 1 - The core viewpoint of the report is that Bank of America Securities maintains a "underperform" rating for China COSCO Shipping Holdings (1919.HK) while adjusting the target price based on a price-to-book ratio increase from 0.65x to 0.75x, keeping the target price at HKD 13.5 [1] - The earnings per share forecast for China COSCO Shipping Holdings for 2026 to 2028 has been slightly adjusted upwards by less than 1% to reflect the performance in the second half of 2025 [1] - The net profit forecast for 2026 is set at RMB 17 billion [1]